Small cap biotech companies spend hundreds of millions of dollars and over ten years moving experimental drug candidates from concept to fully approved drugs. For late stage drug candidates, those in Phase III, positive or negative data can result in either massive gains or devastating declines in the sponsoring company's stock price. This "ultimate catalyst event" provides smart, organized & nimble option traders spectacular & consistent trading opportunities. In this unique book, the author provides individuals unfamiliar with the world of small cap biotech a fast, simplified and efficient...